Douglas J MacNeil

Douglas J MacNeil

UNVERIFIED PROFILE

Are you Douglas J MacNeil?   Register this Author

Register author
Douglas J MacNeil

Douglas J MacNeil

Publications by authors named "Douglas J MacNeil"

Are you Douglas J MacNeil?   Register this Author

46Publications

871Reads

43Profile Views

The role of melanin-concentrating hormone and its receptors in energy homeostasis.

Front Endocrinol (Lausanne) 2013 22;4:49. Epub 2013 Apr 22.

Department of In Vitro Pharmacology, Merck Research Laboratories Kenilworth, NJ, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fendo.2013.00049DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3631741PMC
April 2013

A miniaturized homogenous assay of mitochondrial membrane potential.

Assay Drug Dev Technol 2011 Aug 6;9(4):373-81. Epub 2011 Feb 6.

Obesity Department, Merck Sharp and Dohme Corp., Rahway, New Jersey, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/adt.2010.0301DOI Listing
August 2011

Discovery of pyrimidine carboxamides as potent and selective CCK1 receptor agonists.

Bioorg Med Chem Lett 2011 May 31;21(10):2911-5. Epub 2011 Mar 31.

Department of Medicinal Chemistry, Merck & Co. Inc., PO Box 2000, Rahway, NJ 07065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2011.03.069DOI Listing
May 2011

Pancreatic polypeptide enhances colonic muscle contraction and fecal output through neuropeptide Y Y4 receptor in mice.

Eur J Pharmacol 2010 Feb 8;627(1-3):258-64. Epub 2009 Oct 8.

Tsukuba Research Institute, Banyu Pharmaceutical Co., Ltd., Tsukuba, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejphar.2009.09.057DOI Listing
February 2010

MCH receptor peptide agonists and antagonists.

Peptides 2009 Nov 4;30(11):2008-13. Epub 2009 May 4.

Department of Metabolic Disorders, Merck Research Laboratories, Rahway, NJ 07065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.peptides.2009.04.009DOI Listing
November 2009

In vivo optical imaging of LacZ expression using lacZ transgenic mice.

Assay Drug Dev Technol 2009 Aug;7(4):391-9

Imaging, Merck Research Laboratories, West Point, Pennsylvania 19486, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/adt.2009.0195DOI Listing
August 2009

2-Substituted piperazine-derived imidazole carboxamides as potent and selective CCK1R agonists for the treatment of obesity.

Bioorg Med Chem Lett 2008 Sep 24;18(17):4833-7. Epub 2008 Jul 24.

Department of Medicinal Chemistry, Merck & Co., Inc., 126 East Lincoln Ave., PO Box 2000, Rahway, NJ 07065-0900, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2008.07.083DOI Listing
September 2008

Antagonism of central melanin-concentrating hormone 1 receptor alleviates steatohepatitis in mice.

J Endocrinol 2008 Aug 3;198(2):309-15. Epub 2008 Jun 3.

Tsukuba Research Institute Tsukuba Safety Assessment Laboratories, Banyu Pharmaceutical Co., Ltd, 3 Okubo, Tsukuba 300-2611, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1677/JOE-08-0087DOI Listing
August 2008

Deficiency in cytosolic malic enzyme does not increase acetaminophen-induced hepato-toxicity.

Basic Clin Pharmacol Toxicol 2008 Jul 1;103(1):36-42. Epub 2008 Jul 1.

Department of Metabolic Disorders, Merck Research Laboratories, Rahway, NJ, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1742-7843.2008.00228.xDOI Listing
July 2008

NPY Y1 and Y5 receptor selective antagonists as anti-obesity drugs.

Curr Top Med Chem 2007 ;7(17):1721-33

Merck Research Laboratories, 80M-213, Rahway, NJ 07065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/156802607782341028DOI Listing
February 2008

Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults.

J Clin Endocrinol Metab 2007 May 6;92(5):1754-7. Epub 2007 Mar 6.

Clinical Research, Metabolism, Merck Research Laboratories, 126 East Lincoln Avenue, P.O. Box 2000, RY34A-A202, Rahway, NJ 07065-0900, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/jc.2006-1806DOI Listing
May 2007

4-Aminoquinoline melanin-concentrating hormone 1-receptor (MCH1R) antagonists.

Bioorg Med Chem Lett 2006 Oct 17;16(20):5275-9. Epub 2006 Aug 17.

Department of Medicinal Chemistry, Merck Research Laboratories, PO Box 2000, Rahway, NJ 07065-0900, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2006.08.008DOI Listing
October 2006

Therapeutic potential of histamine H3 receptor agonist for the treatment of obesity and diabetes mellitus.

Proc Natl Acad Sci U S A 2006 Sep 5;103(37):13866-71. Epub 2006 Sep 5.

Tsukuba Research Institute, Banyu Pharmaceutical Company, Ltd., Tsukuba, Ibaraki 300-2611, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.0506104103DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1560086PMC
September 2006

NPY and energy homeostasis: an opportunity for novel anti-obesity therapies.

EXS 2006 (95):143-56

Metabolic Disorders, Merck Research Laboratories, Rahway, NJ 07090, USA.

View Article

Download full-text PDF

Source
February 2006

Detailed pharmacological characterization of GT-2331 for the rat histamine H3 receptor.

Eur J Pharmacol 2006 Jan 28;529(1-3):40-6. Epub 2005 Nov 28.

Tsukuba Research Institute, Banyu Pharmaceutical Co., Ltd., Tsukuba, Ibaraki 300-2611, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejphar.2005.10.066DOI Listing
January 2006

Diet induction of monocyte chemoattractant protein-1 and its impact on obesity.

Obes Res 2005 Aug;13(8):1311-20

Department of Metabolic Disorders, Merck Research Laboratories, Rahway, NJ 07065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/oby.2005.159DOI Listing
August 2005

Antiobesity effect of a melanin-concentrating hormone 1 receptor antagonist in diet-induced obese mice.

Endocrinology 2005 Jul 7;146(7):3080-6. Epub 2005 Apr 7.

Tsukuba Research Institute, Banyu Pharmaceutical Co., Ltd., Okubo 3, Tsukuba 300-2611, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/en.2004-1150DOI Listing
July 2005

Peripheral and central administration of a selective neuropeptide Y Y1 receptor antagonist suppresses ethanol intake by C57BL/6J mice.

Alcohol Clin Exp Res 2004 Sep;28(9):1324-30

Department of Psychology, University of North Carolina, Chapel Hill, North Carolina 27599-3270, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1360243PMC
http://dx.doi.org/10.1097/01.alc.0000139829.67958.1aDOI Listing
September 2004

Chronic administration of nalmefene leads to increased food intake and body weight gain in mice.

Eur J Pharmacol 2004 Jul;495(1):63-6

Department of Metabolic Disorders, Merck Research Laboratories, P.O. Box 2000, RY80M-213, Rahway, NJ 07065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejphar.2004.05.025DOI Listing
July 2004

Synergistic effects of cannabinoid inverse agonist AM251 and opioid antagonist nalmefene on food intake in mice.

Brain Res 2004 Mar;999(2):227-30

Department of Metabolic Disorders, PO Box 2000, RY80M-213, Rahway, NJ 07065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.brainres.2003.12.004DOI Listing
March 2004

The role of tryptophan 1072 in human PDE3B inhibitor binding.

Biochem Biophys Res Commun 2003 Aug;307(4):1045-50

Department of Metabolic Disorders, Merck Research Laboratories, P.O. Box 2000, Mailstop: RY80M-213, Rahway, NJ 07065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0006-291x(03)01299-3DOI Listing
August 2003